Kalytera Therapeutics Inc.
(TSX: V.KALY,OTCQB: KALTF,Forum) on Tuesday unveiled its new Strategic & Scientific Advisory Board. The board will work closely with Kalytera’s management to advance the Company’s cannabinoid-based technology to treat acute and chronic pain. The Company is also looking into new applications for its technology in the health treatment space.
More information on this can be found
here.
Kalytera was in the news recently when it announced that it had been issued a
second patent covering the use of cannabidiol (CBD) for the prevention and treatment of graft versus host disease.
FULL DISCLOSURE: Kalytera Therapeutics Inc. is a paid client of Stockhouse Publishing.